title: First CDK 4/6 Inhibitor Heads to Market.
abstract: The FDA granted accelerated approval to palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women who have not yet received endocrine-based therapy. Palbociclib is the first cell cycle-targeting CDK 4/6 inhibitor to reach the market.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors*; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors*; D017277:Drug Approval; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6